Inhibition of plasma kallikrein by CI-inhibitor: Role of endothelial cells and the amino-terminal domain of CI-inhibitor

Thrombosis and Haemostasis

Volumn 92, Issue 6, 2004, Pages 1277-1283

  Ravindran, Sriram ^a   Grys, Thomas E ^b   Welch, Rodney A ^b   Schapira, Marc ^c   Patston, Philip A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Coagulation inhibitors; Contact phase; Endothelial cells; Proteases inhibitors

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; HIGH MOLECULAR WEIGHT KININOGEN; KALLIKREIN; METALLOPROTEINASE; PREKALLIKREIN;

AMINO TERMINAL SEQUENCE; ANGIONEUROTIC EDEMA; ARTICLE; CELL CULTURE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANGIONEUROTIC EDEMA; CELLS, CULTURED; CHLORINE; COAGULANTS; COMPLEMENT C1 INACTIVATOR PROTEINS; COMPLEMENT C1 INHIBITOR PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOTHELIUM, VASCULAR; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; HETEROZYGOTE; HUMANS; KALLIKREINS; KINETICS; METALLOENDOPEPTIDASES; PROTEIN STRUCTURE, TERTIARY; TIME FACTORS; UMBILICAL VEINS;

EID: 10444240277     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-01-0008     Document Type: Article

References (34)

1. Carugati A, Pappalardo E, Zingale LC, et al. C1-inhibitor deficiency and angioedema. Mol Immunol 2001; 38: 161-73.
2. Cicardi M, Igarashi T, Rosen FS, et al. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J Clin Invest 1987; 79: 698-702.
3. Kramer J, Rosen FS, Cohen HR, et al. Transinhibition of C1 inhibitor synthesis in type I hereditary angioneurotic edema. J Clin Invest 1993; 91: 1258-62.
4. Pappalardo E, Zingale LC, Cicardi M. C1 inhibitor gene expression in patients with hereditary angioedema: Quantitative evaluation by means of real-time RT-PCR. J Allergy Clin Immunol 2004; 114: 638-44.
5. Pappalardo E, Zingale LC, Terlizzi A, et al. Mechanisms of C1-inhibitor deficiency. Immunobiology 2002; 205: 542-51.
6. Davis AE 3rd. The pathogenesis of hereditary angioedema. Transfusion Apher Sci 2003; 29: 195-203.
7. Motta G, Rojkjaer R, Hasan AAK, et al. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: A novel mechanism for contact activation. Blood 1998; 91: 516-28.
8. Schmaier AH, Røjkjær R, Shariat-Madar Z. Activation of the plasma kallikrein/kinin system on cells: A revised hypothesis. Thromb Haemost 1999; 82: 226-33.
9. Schmaier AH. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J Clin Invest 2002; 109: 1007-9.
10. Shariat-Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002; 277; 17962-9.
11. Moreira CR, Schmaier AH, Mahdi F, et al. Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. FEBS Lett 2002; 523: 167-70.
12. Joseph K, Ghebrehiwet B, Kaplan AP. Activation of the kinin-forming cascade on the surface of endothelial cells. Biol Chem 2001; 382: 71-5.
13. Joseph K, Tholanikunnel BG, Kaplan AP. Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII. Proc Natl Acad Sci USA 2002; 99: 896-900.
14. Mahdi F, Shariat-Madar Z, Figueroa CD, et al. Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes. Blood 2002; 99: 3585-96.
15. Rojkjaer R, Hasan AA, Motta G, et al. Factor XII does not initiate prekallikrein activation on endothelial cells. Thromb Haemost 1998; 80: 74-81.
16. Schapira M, Scott CF, Colman RW. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J Clin Invest 1982; 69: 462-8.
17. van der Graaf F, Koedam JA, Bouma BN. Inactivation of kallikrein in human plasma. J Clin Invest 1983; 71: 149-58.
18. 2-macroglobulin-kallikrein complexes. J Biol Chem 1985; 260: 4257-63.
19. van der Graaf F, Koedam JA, Griffin JH, et al. Interaction of human plasma kallikrein and its light chain with C1 inhibitor. Biochemistry 1983; 22: 4860-6.
20. Wachtfogel Y, Harpel PC, Edmunds Jr H, et al. Formation of C1s-C1-inhibitor, kallikrein-C1-inhibitor, and plasmin-α2-plasmin-inhibitor complexes during cardiopulmonary bypass. Blood 1989; 73: 468-71.
21. Veloso D, Colman RW. Western blot analyses of prekallikrein and its activation products in human plasma. Thromb Haemost 1991; 65: 382-8.
22. Brown EW, Ravindran S, Patston PA. The reaction between plasmin and C1-inhibitor results in plasmin inhibition by the serpin mechanism. Blood Coag Fibrinolys 2002; 13: 711-4.
23. Lathem WW, Grys TE, Witowski SE, et al. StcE, a metalloprotease secreted by Escherichia coli O157:H7, specifically cleaves C1 esterase inhibitor. Mol Microbiol 2002; 45: 277-88.
24. Patston PA, Gettins P, Beechem J, et al. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry 1991; 30: 8876-82.
25. 1-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1. Protein Sci 2002; 11: 2230-6.
26. van der Graaf F, Tans G, Bouma BN, et al. Isolation and functional properties of the heavy and light chains of human plasma kallikrein. J Biol Chem 1982; 257: 14300-5.
27. Schousboe I. Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor. Eur J Biochem 2003; 270: 111-8.
28. Lathem WW, Bergsbaken T, Welch RA. Potentiation of C1 esterase inhibitor by StcE, a metalloprotease secreted by Escherichia coli O157:H7. J Exp Med 2004; 199: 1077-87.
29. Bock SC, Skriver K, Nielsen E, et al. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986; 25: 4292-301.
30. Perkins SJ, Smith KF, Amatayakul S, et al. Two-domain structure of the native and reactive centre cleaved forms of C1 inhibitor of human complement by neutron scattering. J Mol Biol 1990; 214: 751-63.
31. Liu D, Cai S, Gu X, et al. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 2003; 171: 2594-601.
32. Liu D, Gu X, Scafidi J, et al. N-linked glycosylation is required for C1 inhibitor-mediated protection from endotoxin shock in mice. Infect Immun 2004; 72: 1946-55.
33. Han ED, MacFarlane RC, Mulligan AN, et al. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057-63.
34. Cugno M, Nussberger J, Cicardi M, et al. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003; 3: 311-7.